PRAX Stock: Praxis Precision Medicines, Inc. Stock Price, Analysis & Insights
Get live prax stock price $247.99, comprehensive Praxis Precision Medicines, Inc. stock analysis, charts, news, and expert forecast. Real-time prax stock data and investment insights.
Loading chart...
Company Overview
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Company Information
- CEO
- Marcio Silva De'Souza
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 116
Contact Information
- Address
- 99 High Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 2.97)
Business Model & Strategy
Praxis Precision Medicines, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Marcio Silva De'Souza, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Praxis Precision Medicines, Inc. competes in the Biotechnology within the broader Healthcare. With 5.2 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Praxis Precision Medicines, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Praxis Precision Medicines, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Praxis Precision Medicines, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Praxis Precision Medicines, Inc.
- ⚠Investors should consider how Praxis Precision Medicines, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
5.24B
P/E Ratio
-19.12
Beta
2.97
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 5.24B market capitalization
- Trading Volume: 2.88M shares traded today
- Price Range: 52-week range of $26.70 - $277.44
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. (PRAX) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 5.24B, the company represents a significant player in its market. The stock is currently trading at $247.99 with a positivedaily change of 30.54%.
The company's 116 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -19.12, beta of 2.97, and 52-week price range from $26.70 to $277.44when evaluating investment opportunities.
Why Invest in Praxis Precision Medicines, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Marcio Silva De'Souza
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.